Pharma and medtech sectors are concerned about upcoming Goods and Services Tax changes. They anticipate higher operating costs and working capital issues. Rajiv Nath suggests a balanced GST approach for equipment and consumables. Federation of Pharma Entrepreneurs urges lower GST on APIs to avoid inverted duty structure. MSMEs fear blocked funds and slowed growth due to tax imbalances.